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Objective: Regulators of adipose tissue hormones remain incompletely understood, but may include sex
hormones. As adipose tissue hormones have been shown to contribute to numerous metabolic and
cardiovascular disorders, understanding their regulation in midlife women is of clinical importance.
Therefore, we assessed the associations between testosterone (T) and sex hormone binding globulin
(SHBG) with leptin, high molecular weight (HMW) adiponectin, and the soluble form of the leptin receptor
(sOB-R) in healthy midlife women.
Design and Methods: Cross-sectional analyses were performed using data from 1,881 midlife women
(average age 52.6 (62.7) years) attending the sixth Annual follow-up visit of the multiethnic Study of
Women’s Health Across the Nation.
Results: T was weakly negatively associated with both HMW adiponectin and sOB-R (r ¼ 0.12 and r ¼
0.10, respectively; P < 0.001 for both), and positively associated with leptin (r ¼ 0.17; P < 0.001).
SHBG was more strongly and positively associated with both HMW adiponectin and sOB-R (r ¼ 0.29
and r ¼ 0.24, respectively; P < 0.001 for both), and more strongly and negatively associated with leptin (r
¼ 0.27; P < 0.001). Adjustment for fat mass, insulin resistance, or waist circumference only partially
diminished associations with HMW adiponectin and sOB-R, but attenuated associations with leptin. In
conclusion, in these midlife women, lower SHBG values, and to a lesser extent, higher T levels, were
associated with lower, or less favorable, levels of adiponectin and sOB-R, independent of fat mass.
Conclusions: These data suggest that variation in these adipose hormones resulting from lower SHBG
levels, and possibly, though less likely, greater androgenicity, may contribute to susceptibility for
metabolic and cardiovascular outcomes during midlife in women.
Obesity (2013) 21, 629-636. doi:10.1002/oby.2012.109
Introduction
Adipose tissue is well-recognized as an endocrine organ, which
secretes a number of hormones. Two such hormones, adiponectin and
leptin, are secreted solely by adipose tissue, and have been implicated
in metabolic and cardiovascular complications. Adiponectin is lower
among obese individuals, and possesses anti-inflammatory, antidia-
betic, and antiatherogenic properties. Leptin is higher among obese
individuals, thought to be due to leptin resistance, and is associated
with a pro-inflammatory, atherogenic milieu. Regulators of adipose tis-
sue-derived hormones remain poorly understood. While fat mass cer-
tainly regulates adipose tissue hormone levels, it is not the only regula-
tor, evidenced by the fact that adipose hormone levels vary
considerably in people of similar fat mass. Men have less favorable adi-
pose hormone profiles than women, even after accounting for differen-
ces in fat mass (1,2,3), raising the question of whether androgen levels
may regulate adipose hormone levels. Testosterone (T) administration
in men has been shown to decrease both adiponectin and leptin levels
(4,5), and adipose hormone levels in women with polycystic ovary syn-
drome (PCOS), a syndrome whose hallmark is hyperandrogenemia,
have been well-characterized, with similar leptin levels but lower adi-
ponectin levels compared with BMI-matched controls (6,7).
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Prior studies of the associations between sex hormones and adipose tis-
sue hormones have overwhelmingly focused on PCOS women, who
tend to be obese and metabolically dysregulated, leaving the under-
standing of regulators of adipose hormones in normal weight women
relatively unexplored. As some evidence suggests that associations
between androgens and adipose hormones may differ in normal weight
vs. obese individuals (8,9,10), examination of the potential modifying
role of fat mass on androgen-adipose hormone associations is needed.
In addition to being few in number, previous studies in healthy women
have adjusted for BMI, a poor proxy for adiposity levels, and have suf-
fered from relatively small sample sizes and failure to account for
potential confounders such as accompanying insulin resistance levels.
In addition, associations between androgens and soluble leptin receptor
(sOB-R), the primary leptin-carrier protein in the circulation and thus,
a potential regulator of leptin’s effects, have not been examined in
healthy women. Therefore, the purpose of the current study was two-
fold: (i) to examine the associations between T and SHBG with leptin,
high molecular weight (HMW) adiponectin, and sOB-R and(ii) to
examine whether these associations differed in nonobese vs. obese
women. These associations were examined in midlife women partici-
pating in the Study of Women’s Health Across the Nation (SWAN).
Methods and Procedures
Participants
SWAN is a multi-center, longitudinal study to characterize the bio-
logical and psychosocial changes with the menopause in a commu-
nity-based sample. SWAN sites are Boston, Chicago, Detroit, Los
Angeles, Newark, Pittsburgh, and Oakland CA. From 1996 to 1997,
3,302 women aged 42-52 years were enrolled. Each site recruited
white women plus one racial/ethnic group including white, African
American (Pittsburgh, Michigan, and Boston), Chinese (Oakland),
Japanese (UCLA) and Hispanic (Newark—Central American, South
American, and Caribbean origin) women. Complete information on
screening and data collection has been published previously (11).
Briefly, at SWAN baseline, women had an intact uterus and were
still menstruating, had at least one ovary and were not pregnant or
breastfeeding. Exclusion criteria included oral contraceptive or sex
steroid hormone therapy use in the prior 3 months. Institutional
review board approval and informed consent was obtained.
With the exception of race-ethnicity and highest grade level achieved,
which were assessed at the SWAN baseline examination, the current
report uses sex hormone, adipose tissue hormone, and covariate data
collected at the sixth annual follow-up visit, the only visit at which
adipose hormones were available on the full SWAN cohort. Among
the 2,441 women who attended the sixth annual visit, blood samples
were available and adipose hormone data were able to be assayed on
2,028 women, with 1,950 having data on all three adipose hormones
of interest. After excluding 69 women missing key covariates of inter-
est, data from 1,881 women were available for the current analyses.
Body size and composition measures
Height and weight were measured in light clothing without shoes and
using calibrated scales. BMI was calculated as weight in kilograms di-
vided by height in m2. Waist circumference was measured in nonrestric-
tive undergarments, or in cases where respondents refused, measures
were taken over light clothing. Waist circumference was measured at
the level of the natural waist, defined as the narrowest part of the torso
as seen from the anterior aspect. In cases where a waist narrowing was
difficult to identify, the measure was taken at the smallest horizontal
circumference in the area between the ribs and the iliac crest. Fat mass
was estimated from bioelectrical impedance analysis (BIA) (BIA-103
analyzer; RJL Systems, Mt. Clemens, MI). BIA is based on measure-
ment of the conductivity of an electrical pulse between electrodes
attached at the feet and the knuckles of the hand. Electrical conductivity
is greater in fat-free than in fat mass, and thereby resistance and react-
ance can be used to estimate fat and lean mass (12,13). Sex-specific val-
idation equations of Chumlea et al. were used (14).
Questionnaire data
Menopause status was assessed based on menstrual bleeding and use
of hormone therapy as follows:
• Pre- or early-perimenopause: monthly bleeding with or without a
perceived change in cycle interval, but at least one period within
the past 3 months.
• Late perimenopause:  three consecutive months of amenorrhea.
• Post menopause:  12 consecutive months of amenorrhea.
• Surgical menopause: menopause induced by hysterectomy with or
without oophorectomy
• Unknown: use of menopausal hormone therapy (MHT) among
pre- or early-perimenopasual women
Smoking was assessed by questionnaire and coded as never, past, or
current. Physical activity was based on the Kaiser Permanente
Activity Score (15).
Assays
Fasting blood draws were targeted to the follicular phase of the
menstrual cycle (days 2-5) and maintained at 4 C until separated and
frozen at 80 C. T, sex hormone binding globulin (SHBG), and
estradiol were assayed at the University of Michigan Endocrine Labo-
ratory using an ACS-180 automated chemiluminescence analyzer
(Bayer Diagnostics, Norwood, MA), with modifications to enhance
sensitivity in the low ranges. To avoid disproportionate exclusion of
women with low hormone values, imputation of hormone values
below the lower limit of detection (n ¼ 8 for SHBG and n ¼ 3 for T)
was performed (16), such that a random value between zero and the
lower limit of detection was used for these women.
Leptin, sOB-R, and HMW adiponectin were determined in the labora-
tory of Dr. Peter Mancuso in duplicate using commercially available
colorimetric enzyme immunoassay kits according to the manufac-
turer’s instructions (leptin and HMW adiponectin; Millipore, St.
Charles, MO and sOB-R; R&D systems, Minneapolis, MN). The mean
coefficient of variation percent for duplicate samples for each subject
and lower limit of detection, respectively, were HMW adiponectin:
8.1%, 0.5 ng/ml; leptin: 4%, 0.5 ng/ml; and sOB-R: 3.7%, 0.31 ng/ml.
Serum insulin level was measured using a solid-phase radioimmuno-
assay (DPC Coat-A-Count Insulin RIA; Diagnostic Products, Los
Angeles, CA). Glucose levels were measured using a hexokinase-
coupled reaction (Boehringer Mannheim Diagnostics, Indianapolis,
IN). The homeostasis model assessment insulin resistance index
(HOMA-IR) was calculated from fasting insulin and glucose as
(fasting insulin (mU/l)  fasting glucose (mmol/l))/22.5.
Statistical methods
Characteristics of the study population were summarized as fre-
quency (%), mean (s.d.) for normally distributed variables, or as
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median (interquartile range) for skewed variables in the overall sam-
ple as well as in nonobese (BMI < 30 kg/m2) and obese (BMI  30
kg/m2) women, separately. v2 tests for categorical variables, t-tests
for normally distributed continuous variables, and Wilcoxon tests for
skewed continuous variables were used to evaluate whether differen-
ces in characteristics between nonobese and obese women were stat-
istically significant.
Median (interquartile range) adipose hormone values were calculated
by quartiles of testosterone and SHBG. P values for linear trend
across quartiles were calculated using the median sex hormone value
in each quartile as a continuous variable in the context of linear
regression modeling, whereby log-transformed adipose hormones
were dependent variables.
Partial Spearman correlation coefficients were then calculated for
associations between testosterone, and SHBG with adipose tissue
hormones, initially adjusting for age, race-ethnicity, site, cycle day
of blood draw, menopausal status, physical activity, smoking status,
and education level. Additional adjustments were made for fat
mass, HOMA-IR, or waist circumference. To insure that SHBG
was not acting as a proxy for estradiol, further adjustment of the
correlation coefficient was also made for estradiol. Correlation
coefficients were calculated for each sex hormone and each adipose
hormone separately. Following this, for each adipose hormone,
partial correlation coefficients were adjusted for values of the other
sex hormone, and separately for values of the other adipose
hormones.
To examine whether associations between testosterone and SHBG
with adipose tissue hormones differed by body size, stratified analy-
ses were performed whereby partial correlation coefficients between
testosterone and SHBG with adipose tissue hormones were calcu-
lated in obese and nonobese women, separately. To formally evalu-
ate potential effect modification, multiplicative interaction terms
were tested for logged values of testosterone and SHBG with a cate-
gorical BMI variable (<30 kg/m2 (nonobese) vs. 30 kg/m2
(obese)) (log(SHBG)  BMI category and log(T)  BMI category)
in the context of log-adipose hormone linear regression models.
Similar interaction terms were tested with race-ethnicity and meno-
pausal status to evaluate effect modification by each of these.
Sensitivity analyses examined the consistency of the findings when
women reporting hysterectomy or MHT use were excluded, and
when BMI was adjusted for instead of fat mass. Additional sensitiv-
ity analyses repeated calculation of correlation coefficients excluding
the 82 women with a high probability of PCOS, per their designa-
tion as having hyperandrogenemic oligomenorrhea, defined as
having total testosterone values in the highest tertile of the cohort
distribution, and a reported history of oligomenorrhea, defined as
3 months without a menstrual period between the ages of 25 and
35 years in the context of a negative report of pregnancy, breast-
feeding, or birth control use during those months, and exclusion of
other causes such as abnormal thyroid stimulating hormone using
National Institutes of Health criteria.
Results
By the sixth annual follow-up visit at which these cross-sectional
analyses took place, SWAN women were an average of 52.6 years
old, 51% were white, 28% African American, 9% Chinese, 11%
Japanese, and <1% Hispanic (Table 1). Over one-third of women
were still premenopausal or early-perimenopausal and were not
using MHT, while close to 50% had undergone surgical or natural
menopause, and 8% reported MHT use since the last study visit.
When stratified by body size, obese women (BMI  30 kg/m2) were
more often African American, had lower education levels, were less
often still pre- or early-perimenopausal, and had higher fat mass,
waist circumference, HOMA, testosterone, and leptin values; and
lower SHBG, sOB-R, and HMW adiponectin values compared with
nonobese women (BMI < 30 kg/m2; Table 1).
HMW adiponectin and sOB-R were both negatively correlated with
BMI, fat mass, and waist circumference (Supplementary Table S1
online; Spearman correlation coefficients ranging from 0.33 to
0.43; all P < 0.001), while leptin levels were positively correlated
with indices of body size and adiposity (correlation coefficients
ranging from 0.82 to 0.86). In addition, each of the adipose tissue
hormones was significantly associated with the others, with HMW
adiponectin significantly positively associated with sOB-R (correla-
tion coefficient 0.45, P < 0.001), and significantly negatively
correlated with leptin (correlation coefficient -0.34; P < 0.001), and
leptin and sOB-R similarly negatively correlated (correlation coeffi-
cient 0.42; P < 0.001).
With higher testosterone quartiles, HMW adiponectin and sOB-R
levels were lower, whereas leptin levels were higher (Table 2).
Opposite results were found with higher SHBG quartiles. After
multivariate adjustment which included not only age, race-ethnic-
ity, menopausal status, physical activity, smoking status, education
level, cycle day of blood draw, and study site, but also fat mass,
and subsequent models including waist circumference or HOMA-
IR, HMW adiponectin levels were lower and leptin levels higher
with higher testosterone levels, though the magnitude of associa-
tions were considerably reduced with adjustment for fat mass or
HOMA-IR (Table 3). The magnitude of correlation coefficients
was similar after further adjustment of testosterone results for
SHBG.
After initial adjustment for age, race-ethnicity, menopausal status,
physical activity, smoking status, education level, cycle day of blood
draw, and study site, SHBG was positively associated with HMW
adiponectin and sOB-R, and negatively associated with leptin. As
above, the association with leptin was substantially attenuated with
adjustment for fat mass. However, the positive associations between
SHBG and both HMW adiponectin and sOB-R were quite robust to
additional adjustment not only for fat mass, but also for HOMA-IR,
waist circumference, and testosterone. Results were also additionally
adjusted for estradiol to insure that SHBG was not acting as a proxy
for estradiol, and results were, again, similar (partial correlation
coefficients of 0.24 and 0.17 for HMW adiponectin and sOB-R,
respectively, after additional adjustment for estradiol; both P <
0.001).
When all three adipose hormones were also adjusted for each other
(Table 3, partial 6), HMW adiponectin results were only slightly
attenuated. The positive association between testosterone and leptin
was unchanged, while the negative association between SHBG and
leptin was only slightly attenuated, but lost statistical significance.
The opposite finding was true for sOB-R; the negative association
with testosterone was only slightly attenuated but lost statistical
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significance, while the positive association with SHBG was slightly
attenuated, but remained statistically significant.
We also examined effect modification of these associations by
body size, race-ethnicity, and menopausal status in models adjusted
for the factors listed above as well as fat mass. Significant interac-
tion terms were found for body size concerning the associations
between SHBG with both leptin (P-interaction < 0.001) and sOB-
R (P-interaction ¼ 0.025). For leptin, a negative association was
found with SHBG in nonobese participants (Table 4; r ¼ 0.11),
but a weak positive association in obese participants (Table 4; r ¼
0.08). For sOB-R, a positive association was found with SHBG in
nonobese participants (Table 4; r ¼ 0.19), but a null association in
obese participants (Table 4; r ¼ 0.05). Body size interaction terms
were not statistically significant for associations between T and
any of the adipose tissue hormones, or between SHBG and HMW
adiponectin.
Significant interaction terms were also found for race-ethnic effects
on the associations between SHBG and leptin (P ¼ 0.006), and tes-
tosterone and sOB-R (P ¼ 0.009). When stratified by race-ethnicity,
partial correlation coefficients between SHBG and leptin were simi-
lar in magnitude among African American and white women (r ¼
0.02 and 0.06, respectively), but were stronger in Chinese and
Japanese women (r ¼ 0.10 and 0.18, respectively). For the asso-
ciation between testosterone and sOB-R, it appeared to be null for
all, but the Japanese, in whom it was negative (r ¼ 0.13). Signifi-
cant interactions were not detected for menopausal status, indicating
that associations between sex hormones and adipose tissue hormones
were similar within each of the menopause status categories.
TABLE 1 Characteristics of the study population at the sixth annual SWAN visit
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Results were similar when women reporting hysterectomy or MHT
use were excluded from analyses, when BMI was adjusted for
instead of fat mass, and when the 82 suspected PCOS cases were
excluded.
Discussion
Testosterone receptors have been found in various tissues, includ-
ing adipose tissue (17), raising the possibility that testosterone
may serve as a regulator of adipose tissue hormones. SHBG is a
liver-derived binding and transport protein for both testosterone
and estradiol, though it has greater affinity for testosterone (18).
However, in addition to binding sex steroids and, therefore, deter-
mining the amount of free steroid, SHBG has also been shown to
bind to membrane receptor sites, itself, raising the possibility that
SHBG may have direct effects on cell signaling independent of
its influence on the biologic activity of estradiol and testosterone
(19). Therefore, like testosterone, SHBG is also a potential regu-
lator of adipose tissue hormone levels. However, few investiga-
tions have examined the relationships between testosterone or
SHBG and adipose tissue hormones in healthy women. Among
these midlife women, we found that higher testosterone levels
and lower SHBG levels were associated with lower HMW adipo-
nectin and sOB-R levels, and higher leptin levels, independent of
levels of fat mass, and in most cases, independent of HOMA-IR
and waist circumference as well. Therefore, our data support the
possibility that SHBG and testosterone may regulate adipose
tissue hormones.
The strongest associations documented in these midlife women were
between SHBG and both HMW adiponectin and sOB-R, whereby
even after adjustment for fat mass, HOMA-IR, waist circumference,
testosterone, or estradiol partial correlation coefficients were 0.20
for HMW adiponectin and 0.15 for sOB-R. In agreement with our
findings, several studies have documented a significant positive
association between SHBG and adiponectin (20-23). To our knowl-
edge, prior published reports have not examined the association
between SHBG and sOB-R. SOB-R is the primary carrier protein
for leptin in the blood stream, and is a cleaved derivative of mem-
brane-anchored leptin receptors. The scope of the physiologic role
of sOB-R is still largely unknown. Higher sOB-R levels may
TABLE 2 Median (25th percentile, 75th percentile) adipose hormone values by quartiles of testosterone and SHBG
TABLE 3 Spearman partial correlation coefficients between adipose hormones and testosterone and SHBG
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contribute to leptin resistance and, in part, determine the extent of
leptin’s effects; sOB-R is thought to delay leptin clearance, increas-
ing circulating leptin concentrations, but decreasing the availability
of biologically active leptin, which is the free rather than bound
form (24). Despite this, the association between SHBG and sOB-R
was independent of leptin levels, suggesting that sOB-R may have
associations with biological factors through means other than its reg-
ulation of leptin levels. SHBG and sOB-R may be linked through
liver-specific pathways; although in fairly low levels, the short form
of the leptin receptor has been observed in liver tissue, adjacent to
the hepatic vessels (25) and, as we noted above, the liver is the site
of SHBG production.
Although statistically significant, we found much weaker associa-
tions between testosterone and adipose hormones than was observed
between SHBG and adipose hormones, especially after adjustment
for fat mass, perhaps suggesting lesser biological relevance of
testosterone compared with SHBG in relation to adipose tissue hor-
mone pathways. The vast majority of prior research on the potential
regulation of adipose hormones by androgens has occurred in men
or in women with PCOS. There have been a limited number of
investigations into the associations between androgens and adiponec-
tin in healthy women, and results have been inconsistent, including
reports of both negative and positive associations, as well as null
findings (20-24,26-29). The reasons for these discrepancies are
unclear. Adiponectin is a multimeric complex, forming trimers (low
molecular weight), hexamers (medium molecular weight), and multi-
mers (HMW). In human plasma, the low molecular weight and
HMW forms are the most abundant, and the HMW form of adipo-
nectin is suggested to be the most biologically active form (30). All
but one of the cited studies reported relationships between testoster-
one and total adiponectin, with each of these reporting null or posi-
tive associations. The single study reporting associations with the
HMW adiponectin form was the only study to demonstrate a nega-
tive association with testosterone similar to our findings, but found
it only with the ratio of HMW to total adiponectin, rather than with
raw HMW adiponectin levels, alone, as we report (26). Therefore,
the failure of most prior studies to examine the HMW adiponectin
form, specifically, may partially underlie discrepant results.
In contrast to contradictory findings of an association between tes-
tosterone and HMW adiponectin, the positive relationship we report
between testosterone and leptin is consistent with prior findings
among healthy women (10,27,31,32). To our knowledge, only one
other published report has examined the relationship between
circulating testosterone and sOB-R levels, finding the same negative
relationship we saw, even after adjustment for fat mass among a
sample of adolescents and young adults (33).
Although associations between testosterone and adipose tissue hor-
mones were fairly weak, the presence of androgen receptors in both
adipocytes and preadipocytes supports the possibility of a regulatory
relationship between testosterone and adipose tissue hormones (17).
Androgen receptor density is greater in visceral compared with
subcutaneous fat (17). Given that visceral adipose tissue secretes
pro-inflammatory adipokines in greater quantity, and anti-inflamma-
tory adiponectin in lesser quantity than subcutaneous adipose tissue
(34,35), it may be that testosterone binding to visceral adipocytes
initiates adverse changes to the hormone secretion profile of adipose
tissue. In accordance with the negative association we report
between testosterone and HMW adiponectin, testosterone adminis-
tration has been shown to decrease adiponectin secretion, due to the
enhanced intracellular retention of the HMW adiponectin multimer,
specifically (36). However, in contrast to the positive association we
document between testosterone and leptin, testosterone exposure
suppressed leptin gene expression in human adipocytes (37).
It is also possible that the cross-sectional associations we document
here represent regulation of testosterone and SHBG levels by
adipose hormones. Conversion of androgens to estrogens via aroma-
tization occurs in adipose tissue. However, again possible mecha-
nisms support a negative, rather than positive, feedback loop
between leptin and testosterone; leptin may stimulate aromatase
expression and depending on the precursor, decrease circulating
androgen levels (38). As regards regulation of SHBG by adipose
hormones, in addition to regulation by testosterone and estradiol,
both leptin and adiponectin receptors have been documented in the
liver, the site of SHBG production (25,39).
Prior published data suggest effect modification of sex hormone-
adipose hormone relationships by body size. A synergistic
relationship was described for free testosterone and waist:hip ratio
associations with HMW adiponectin among women with PCOS,
whereby women with both high free testosterone and high waist:hip
ratio had the lowest HMW adiponectin values (9). For leptin, posi-
tive associations between total and free testosterone have been
reported in nonobese, whereas null or negative associations are
reported in obese (8,10). We found evidence of effect modification
of the associations between SHBG and both leptin and sOB-R by
body size; SHBG was negatively associated with leptin and posi-
tively associated with sOB-R in nonobese, but positively associated
with leptin, and not associated with sOB-R in obese. The opposing
TABLE 4 Spearman partial correlation coefficients between adipose hormones and testosterone and SHBG, stratified by BMI
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direction of the association between SHBG and leptin in obese vs.
nonobese individuals may relate to the loss of leptin sensitivity in
obese individuals; High leptin levels in obese individuals are thought
to be due to leptin resistance, while in nonobese individuals they
may represent functional leptin involved in appropriate feedback
responses. Regarding sOB-R, the null association in obese may also
relate to leptin resistance, whereby dysregulation of the leptin sys-
tem results in loss of association between leptin receptor levels and
regulators of leptin levels. Alternatively, should the current cross-
sectional associations represent regulatory relationships, the null
relationship between SHBG and sOB-R in obese women may also
represent a threshold effect of either SHBG or sOB-R; both SHBG
and sOB-R levels were substantially lower in obese vs. nonobese
women in the current study and may have been too low to elicit any
change in levels of the other.
The current analyses also identified effect modification of SHBG
and T associations with leptin and sOB-R, respectively, by race-
ethnicity, finding the strongest associations among Japanese women.
The biological explanation for this finding is unclear. As these are
cross-sectional analyses and temporality cannot be determined, this
finding may represent either a stronger influence of testosterone and
SHBG on leptin and sOB-R in Japanese women, or a stronger influ-
ence of leptin and sOB-R on testerone and SHBG in Japanese
women. In consideration of the first temporal sequence specified
above, abdominal visceral adipose tissue has been shown to have a
greater density of androgen receptors than subcutaneous adipose
tissue (17). However, Japanese women have strikingly lower waist
circumference values than the other race-ethnic groups represented
in SWAN, and therefore, the lesser abdominal adiposity in Japanese
women might be expected to attenuate the influence of androgens
on adipokines, rather than strengthen it. In reference to the opposite
temporal sequence, namely leptin and sOB-R possibly influencing
testosterone and SHBG more strongly in Japanese women, the Japa-
nese women in SWAN have the lowest BMI, even lower than the
Chinese SWAN women. Given that leptin sensitivity is proportional
to body size, it is conceivable that Japanese women are more sensi-
tive to leptin than the remaining race-ethnic groups. As a result, the
influence of leptin and sOB-R on testosterone and SHBG may be
greater in Japanese women, as reflected in our finding of stronger
associations among Japanese women. Although interaction analyses
were adjusted for fat mass, which should conceivably statistically
account for this effect, it may be that residual confounding by
adiposity remained. Given the number of significance tests per-
formed, these interaction results should be evaluated with extreme
caution and require confirmation by future studies.
The results of the current report must be viewed within the context
of the limitations of the study. We did not measure free testosterone.
This is a cross-sectional study, and therefore, directionality cannot
be inferred. However, this study had a number of strengths. Data
from three adipose hormones were available across a wide range of
BMI. In addition, women of varying menopausal status and ethnicity
were included, and a number of possible confounders not previously
accounted for were included, most importantly HOMA-IR and waist
circumference. Finally, we accounted for adiposity via fat mass,
rather than BMI. BMI cannot distinguish between fat mass and
muscle mass, and therefore, can be a poor proxy for adiposity
particularly in younger and older populations where the degree of
muscle mass may vary substantially between individuals or is chang-
ing within individuals over time. In the current study, results were
similar whether BMI or fat mass was used, suggesting that in these
midlife women, muscle mass was likely not significantly confound-
ing the ability of BMI to approximate fat mass.
In conclusion, these cross-sectional results suggest that unfavorable
adipose hormone levels are seen with higher testosterone and lower
SHBG levels in these midlife women, independent of fat mass and
waist circumference. It is known that individuals of similar body
size can have very different cardiometabolic profiles, potentially
explained in part by different adipose tissue distribution patterns,
receptor densities, or secretory profiles in adipose tissue of different
individuals (40). These data support the possibility that SHBG, and
less likely, though also possible, testosterone, may play a role in
determining the particular hormonal expression profile of adipose
tissue of a given midlife woman. Therefore, alterations in adipose
hormones resulting from alterations in the androgen/estrogen balance
determined by SHBG, independent of increases in body fat, may
partially explain enhanced susceptibility to metabolic and cardiovas-
cular outcomes with the menopause transition, and similarly, that
reduced SHBG levels, independently of any influence on androgen
or estrogen levels, further exacerbate disease susceptibility in
women during midlife. These intriguing data underscore the need
for assessment of the longitudinal relationships between androgens,
SHBG, and adipokines.
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